Abstract:minal Gln amide transfer (GAT) domain and is promoted by the allosteric effector GTP. 3] The resulting nascent NH3 is subsequently transferred to the N-terminal synthase domain via an NH3 tunnel, [4–6] where it reacts with UTP that has been activated by ATP-dependent phosphorylation at the 4-position (i.e. , UTP-4-P). The enzyme exhibits positive cooperativity for ATP and UTP, and these nucleotides act synergistically to promote tetramerization of the enzyme to its active form. The product CTP is a feedback inhibitor of the enzyme and plays an important role in the biosynthesis of nucleic acids, phospholipids, 12] and sialic acid. Consequently, CTPS is a recognized target for the development of antineoplastic, antiviral, and antiprotozoal agents. Although many studies have focused on delineating the regulatory properties of CTPS, very few have focused on the development of nucleotide analogues as inhibitors of this enzyme. 24] 3-Deazauridine 5’-triphosphate (IC50 ~18 mm) and cyclopentenyl cytosine (CPEC) 5’-triphosphate (IC50 ~6 mm) are substrate and product analogues, respectively, that are the most well-studied inhibitors of CTPS. In addition, the 5’-triphosphate of 2’,2’-difluorodeoxycytidine (gemcitabine) is also believed to exert its chemotherapeutic effects, in part, through the inhibition of CTPS. 28] However, mutations in CTPS lead to the loss of feedback inhibition by CTP and resistance to the cytotoxic effects of these and other chemotherapy drugs. Therefore, the development of new, potent, and selective CTPS inhibitors such as transition state/intermediate analogues or multivalent inhibitors is required. Enzymes often exhibit high affinity for structural and electronic mimics of transition states or reactive intermediates generated during catalysis. We rationalized that CTPS inhibitors might be developed by employing methylene or difluoromethylene phosphonate groups, or a phosphoramidate group as isosteric and/or isoelectronic replacements for the 4-phosphate group of the UTP-4-P intermediate (Scheme 1). Alternatively, the use of multivalent ligands (e.g. , substrate– product analogues) is often an effective strategy to develop potent and specific enzyme inhibitors, as such inhibitors may interact with multiple binding determinants on the enzyme to afford an entropic advantage in binding. The X-ray crystal structures of Escherichia coli CTPS suggest that UTP and CTP share the same binding pocket for their 5’-triphosphate groups (Figure 1). 49] Consequently, multivalent ligands containing binding determinants of the ribose and pyrimidine moieties of UTP, CTP, or nucleotide analogues are attractive candidates for development as CTPS inhibitors. Herein we Scheme 1. Catalytic mechanism of CTP synthase.

Ground State, Intermediate, and Multivalent Nucleotide Analogue Inhibitors of Cytidine 5′‐Triphosphate Synthase

Combinatorial metabolic engineering of industrial Gluconobacter oxydans DSM2343 for boosting 5-keto-D-gluconic acid accumulation

Metabolic engineering of Escherichia coli for the efficient production of 5-hydroxyvaleric acid

Brain tumors induced by Rous sarcoma virus, Schmidt-Ruppin strain. 3. Morphology of brain tumors induced in adult mice.

High-yield production of L-valine in engineered Escherichia coli by a novel two-stage fermentation

Escherichia coli W as a new platform strain for the enhanced production of L-valine by systems metabolic engineering

Efficient whole-cell catalysis for 5-aminovalerate production from L-lysine by using engineered Escherichia coli with ethanol pretreatment

Efficient L-valine production using systematically metabolic engineered Klebsiella oxytoca

Metabolic engineering of Escherichia coli for the production of 5-aminolevulinic acid based on combined metabolic pathway modification and reporter-guided mutant selection (RGMS)

Directed evolution and metabolic engineering generate an Escherichia coli cell factory for de novo production of 4-hydroxymandelate

Metabolic Engineering of High L-Lysine-Producing Escherichia coli for de Novo Production of L-Lysine-Derived Compounds

Metabolic Engineering of Escherichia coli for Production of 2,5-Dimethylpyrazine

Systems engineering of Escherichia coli for high-level glutarate production from glucose

Metabolic Engineering of Escherichia coli for De Novo Production of 1,5-Pentanediol from Glucose

Substrate-inducible and antibiotic-free high-level 4-hydroxyvaleric acid production in engineered Escherichia coli

L-valine production in Corynebacterium glutamicum based on systematic metabolic engineering: progress and prospects

High production of valencene in Saccharomyces cerevisiae through metabolic engineering

[Metabolic engineering of the substrate utilization pathway in Escherichia coli increases L-lysine production]

Metabolic engineering of Halomonas bluephagenesis for production of five carbon molecular chemicals derived from L-lysine

Optimization of vanillin biosynthesis in Escherichia coli K12 MG1655 through metabolic engineering

Effect of a new long-acting somatostatin analogue (SMS 201–995) on glycemic and hormonal response to a mixed meal in acromegalic patients